Enabling clinical grade manufacturing of gene-engineered NK cells

Published: 5 January 2022
Innovator Insight
Nina Möker,
Rizwan Romee,
Evelyn Ullrich

In the adaptive cell and gene therapy field, T cells are currently receiving a lot of focus and showing success in making it to the market – but natural killer (NK) cells are beginning to close this gap. In particular, CAR NK cells for cancer cell therapy offer a number of distinct advantages. But what benefits, and what challenges, do CAR NK cells pose? In this article and expert discussion the manufacturing, analytics, and functionality of CAR NK cells will be discussed, along with further engineering strategies to overcome some of the obstacles still facing this modality.

Read now